SAN DIEGO, Nov. 11, 2010 /PRNewswire-FirstCall/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) will host investors and analysts in New York City on November 18, 2010 for an in depth discussion on the current management of Clostridium difficile infection and the market opportunity for fidaxomicin. A live webcast of the event beginning at 9:00 a.m. ET will be accessible on the Investors page of the Company's website at www.optimerpharma.com. A replay will be available for 90 days.
The program will feature presentations by:
- Mark Miller, M.D., Head of Infectious Diseases Division and Chair of Infection Prevention and Control Committee, SMBD Jewish Hospital in Montreal
- Pedro Lichtinger, President and CEO, Optimer
- Sherwood Gorbach, M.D., Chief Medical Officer, Optimer and Professor of Public Health & Medicine, Tufts University School of Medicine
(Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)
(Logo: http://www.newscom.com/cgi-bin/prnh/20090413/LA97352LOGO)
For additional information regarding this event, please contact Christina Donaghy, Corporate Communications Manager at Optimer Pharmaceuticals, at [email protected].
About Optimer Pharmaceuticals
Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing hospital specialty products to treat serious infections and address unmet medical needs. Optimer has two anti-infective product candidates in development, fidaxomicin and Pruvel™ (prulifloxacin). Fidaxomicin is a narrow spectrum antibiotic being developed for the treatment of Clostridium difficile infection (CDI). We recently initiated a rolling submission of our NDA filing to the FDA, and filed a MAA with the EMA (Europe) for fidaxomicin. Pruvel™ is a prodrug in the fluoroquinolone class of antibiotics that has completed two Phase 3 trials as a treatment for infectious diarrhea. Additional information can be found at http://www.optimerpharma.com.
Contacts |
|
Optimer Pharmaceuticals, Inc. |
|
Christina Donaghy, Corporate Communications Manager |
|
John D. Prunty, Chief Financial Officer & VP Finance |
|
858-909-0736 |
|
Canale Communications, Inc. |
|
Jason I. Spark, Senior Vice President |
|
619-849-6005 |
|
SOURCE Optimer Pharmaceuticals, Inc.
Share this article